Kawasaki Yukihiko, Hosoya Mitsuaki, Suzuki Junzo, Onishi Noriko, Takahashi Ai, Isome Masato, Nozawa Ruriko, Suzuki Hitoshi
Department of Pediatrics, Fukushima University School of Medicine, Fukushima, Japan.
Am J Nephrol. 2004 Nov-Dec;24(6):576-81. doi: 10.1159/000082202. Epub 2004 Nov 17.
To evaluate the efficacy of prednisolone, warfarin, and dipyridamole therapy combined with mizoribine (PWDM) in the treatment of diffuse immunoglobulin A (IgA) nephropathy in comparison with prednisolone, warfarin, and dipyridamole therapy without mizoribine (PWD) and with methylprednisolone pulse therapy (PWD pulse).
We collected data on 61 patients diagnosed with diffuse IgA nephropathy, and these patients were retrospectively divided into three groups without randomization. Group A included 21 patients before 1987 who were treated with PWD for 24 months, group B included 20 patients from 1987 to 1989 who were treated with PWD pulse therapy for 24 months, and group C included 20 patients after 1990 who were treated with PWDM for 24 months. Clinical features and pathological findings in each group were analyzed retrospectively.
The time from initiation of therapy in group A, group B, and group C was 8.9 +/- 5.2, 8.1 +/- 3.9, and 7.7 +/- 3.8 years, respectively. At the latest follow-up examination, the mean urinary protein excretion (mg/m2/h) was 17 +/- 10 in group A, 22 +/- 20 in group B, and 6 +/- 6 in group C and had decreased significantly in group C as compared with the other groups. The activity index in all three groups was lower at the second biopsy than that at the first biopsy (5.1 +/- 0.8 vs. 6.5 +/- 2.1 in group A, p < 0.05; 5.6 +/- 0.9 vs. 6.6 +/- 1.7 in group B, p < 0.01, and 4.5 +/- 1.0 vs. 6.8 +/- 1.9 in group C, p < 0.01). The chronicity index in groups A and B at second biopsy was higher than at first biopsy (7.3 +/- 1.4 vs. 4.8 +/- 1.0 in group A, p < 0.01, and 8.1 +/- 2.0 vs. 5.3 +/- 0.9 in group B, p < 0.01), but was unchanged in group C. At the latest follow-up examination, 1 patient (4.8%) in group A, 3 patients (15%) in group B, and none (0%) in group C had renal insufficiency.
These results suggest that PWDM appears to be more effective than PWD or PWD pulse in ameliorating proteinuria and histological severity of patients with IgA nephropathy.
评估泼尼松龙、华法林和双嘧达莫联合咪唑立宾(PWDM)治疗弥漫性免疫球蛋白A(IgA)肾病的疗效,并与不使用咪唑立宾的泼尼松龙、华法林和双嘧达莫治疗(PWD)以及甲泼尼龙冲击治疗(PWD脉冲)进行比较。
我们收集了61例诊断为弥漫性IgA肾病患者的数据,这些患者未随机分组,回顾性地分为三组。A组包括1987年以前的21例患者,接受PWD治疗24个月;B组包括1987年至1989年的20例患者,接受PWD脉冲治疗24个月;C组包括1990年以后的20例患者,接受PWDM治疗24个月。对每组的临床特征和病理结果进行回顾性分析。
A组、B组和C组开始治疗的时间分别为8.9±5.2年、8.1±3.9年和7.7±3.8年。在最近一次随访检查时,A组平均尿蛋白排泄量(mg/m²/h)为17±10,B组为22±20,C组为6±6,与其他组相比C组显著降低。所有三组的活动指数在第二次活检时均低于第一次活检时(A组:5.1±0.8对6.5±2.1,p<0.05;B组:5.6±0.9对6.6±1.7,p<0.01;C组:4.5±1.0对6.8±1.9,p<0.01)。A组和B组第二次活检时的慢性指数高于第一次活检时(A组:7.3±1.4对4.8±1.0,p<0.01;B组:8.1±2.0对5.3±0.9,p<